JFS Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

JFS Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-33	Closed	-$1.04K	–	2210
2026 Q2	$1.04K	Buy	33 +30	+1,000%	+$885	﹤0.01%	1799
2026 Q1	$75	Hold	3	–	–	﹤0.01%	1852
2025 Q4	$71	Hold	3	–	–	﹤0.01%	1894
2025 Q3	$60	Hold	3	–	–	﹤0.01%	1861
2025 Q2	$66	Hold	3	–	–	﹤0.01%	1824
2025 Q1	$73	Hold	3	–	–	﹤0.01%	1886
2024 Q4	$63	Hold	3	–	–	﹤0.01%	1904
2024 Q3	$60	Hold	3	–	–	﹤0.01%	1923
2024 Q2	$47	Hold	3	–	–	﹤0.01%	1959
2024 Q1	$48	Sell	3 -2	-40%	-$30	﹤0.01%	1979
2023 Q4	$85	Buy	5 +1	+25%	+$14	﹤0.01%	1961
2023 Q3	$47	Sell	4 -1	-20%	-$13	﹤0.01%	1933
2023 Q2	$68	Buy	5 +4	+400%	+$58	﹤0.01%	1942
2023 Q1	$17	Buy	+1	New	+$16	﹤0.01%	1945

Other funds holding CPRX

Teacher Retirement System of Texas Austin, Texas $37.3B AUM 26.21% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

JFS Wealth Advisors's CPRX Position: Q3 2026 in Review

JFS Wealth Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 33 shares — an estimated $1.04K sold.

JFS Wealth Advisors first reported a position in CPRX in Q1 2023 and held it in 14 quarters. The position peaked at $1.04K in Q2 2026. 3 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

JFS Wealth Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
JFS Wealth Advisors sold 33 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.04K.
JFS Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 14 quarters.
JFS Wealth Advisors's Catalyst Pharmaceutical position peaked at $1.04K in Q2 2026.
3 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on JFS Wealth Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.